LGD-4033 with MK-677(Legal TESTOSTERONE and HGH)

[John Juan]

Stacking LGD-4033 with MK-677 is like stacking testosterone and HGH.
These SARMS are legal to purchase and legit.



LGD-4033 is a selective androgen receptor modulator (SARMS), and a novel non-steroidal oral SARM that binds to the androgen receptor with high affinity and selectivity. LGD-4033 is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration. Doses range from 1mg to 10mg daily. Bodybuilders have put on as much as 10Lbs of lean muscle in a month. A good cycle length of LGD-4033 is 8 weeks. There is minimal shut down with an increase in size, strength, and vascularity.

MK-677 is the most convenient form of HGH on the market.

- It is an oral sublingual HGH Secretagogue
- It only requires one 25mg oral sublingual dose per day
- It puts out over a dozen low wave HGH pulses per 24 hour period
- It is stored at room temperature making it convenient for travel
- Igf-1 increases with each consecutive day of use to extremely high levels
- Body fat seems to melt off
- Weight gain comes quickly
- Sleep is much deeper
- Endurance is greatly improved while training

Growth hormone secretagogue MK-677: no clinical ef... [Neurology. 2008] - PubMed result
Results: Administration of MK-677 25 mg resulted in a 60.1% increase in serum IGF-1 levels at 6 weeks and a 72.9% increase at 12 months.


Effects of an oral ghrelin mimetic on body composi... [Ann Intern Med. 2008] - PubMed result
Results: Over 12 months, the ghrelin mimetic MK-677 enhanced pulsatile growth hormone secretion, significantly increased fat-free mass, and was generally well tolerated. Long-term functional and, ultimately, pharmacoeconomic, studies in elderly persons are indicated.

 

[John Juan]

Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.

Authors
Copinschi G1, Leproult R, Van Onderbergen A, Caufriez A, Cole KY, Schilling LM, Mendel CM, De Lepeleire I, Bolognese JA, Van Cauter E.
Author information
Journal
Neuroendocrinology. 1997 Oct;66(4):278-86.

Affiliation
Abstract
Previous studies have indicated the existence of common mechanisms regulating sleep and somatotropic activity. In the present study, we investigated the effects of prolonged treatment with a novel, orally active, growth hormone secretagogue (MK-677) on sleep quality in healthy young and older adults. Eight young subjects (18-30 years) followed a double-blind, placebo-controlled, three-period crossover design. Each subject participated in three 7-day treatment periods (with bedtime drug administration), presented in random (Latin square) order, and separated by at least 14 days. Doses were 5 and 25 mg MK-677 and matching placebo. Six older subjects, ages 65-71 years, each participated in two 14-day treatment periods (with bedtime drug administration) separated by a 14-day washout. Doses were 2 and 25 mg MK-677 during the first and second periods, respectively. Baseline sleep and hormonal data were obtained on the 2 days preceding the beginning of the first 14-day treatment period. In young subjects, high-dose MK-677 treatment resulted in an approximately 50% increase in the duration of stage IV and in a more than 20% increase in REM sleep as compared to placebo (p < 0.05). The frequency of deviations from normal sleep decreased from 42% under placebo to 8% under high-dose MK-677 (p < 0.03). In older adults, treatment with MK-677 was associated with a nearly 50% increase in REM sleep (p < 0.05) and a decrease in REM latency (p < 0.02). The frequency of deviations from normal sleep also decreased (p < 0.02). The present findings suggest that MK-677 may simultaneously improve sleep quality and correct the relative hyposomatotropism of senescence.

 

[jtmdell]

I've had great results stacking these 2 compounds. The mk-677 is a great way to increase your appetite when bulking.

 

[Elvia1023]

I've had great results stacking these 2 compounds. The mk-677 is a great way to increase your appetite when bulking.

x2

MK-677 is super strong. One of the best GH products on the market (that includes all brands of HGH too). I had to lower my dose from 37.5mg to 25mg as the tiredness become unbearable. But the results are amazing when combined with a good diet and training program.

LGD-4033 is a great compliment to any cycle. It would also be an amazing first cycle for a natural.

 

[John Juan]

I've had great results stacking these 2 compounds. The mk-677 is a great way to increase your appetite when bulking.

It sure is!
It made me so hungry at work that I ate all my prepared meals by 10am and had to run out to get more food. This stack really puts the gains on fast!!!

 

[jtmdell]

When I first started it I would get so hungry that I felt like was going to pass out if I didn't eat something.

Really makes my muscles feel very full and gives a great pump too

 

[John Juan]

When I first started it I would get so hungry that I felt like was going to pass out if I didn't eat something.

Really makes my muscles feel very full and gives a great pump too

That's exactly how I react. It's one powerful stack MK-677 and LGD-4033. You grow extremely fast and simaltaneously drop body fat.

 

[John Juan]

MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.

Authors
Murphy MG1, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR.
Author information
Journal
J Clin Endocrinol Metab. 1998 Feb;83(2):320-5.

Affiliation
Abstract
The reversal of diet-induced negative nitrogen balance by GH suggests a possible therapeutic role for GH treatment in catabolic patients. A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism. Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods. During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily. There was a 14- to 21-day washout interval between periods. During the first week of caloric restriction (i.e. diet alone), daily nitrogen losses were similar for both treatment groups (mean +/- SE; MK-677 group -2.67 +/- 0.40 g/day vs. placebo group -2.83 +/- 0.26 g/day). During the second week (diet and study drug), mean daily nitrogen balance was 0.31 +/- 0.21 g/day in the MK-677 treatment group compared with -1.48 +/- 0.21 g/day in the placebo group (P < 0.01). MK-677 improved nitrogen balance integrated over the 7 days of treatment; area under the curve day 8-14 nitrogen balance response was +2.69 +/- 5.0 (SE) for MK-677 and -8.97 +/- 5.26 g.day for placebo (P < 0.001). MK-677 produced a peak GH response of 55.9 +/- 31.7 micrograms/L after single dose (day 1 of treatment) and 22.6 +/- 9.3 micrograms/L after a week of dosing compared with placebo treatment peak GH values of approximately 9 (treatment day 1) and approximately 7 micrograms/L (treatment day 7). Following the initial 7-day caloric restriction, insulin-like growth factor-I (IGF-I) declined from 232 +/- 25 to 186 +/- 19 ng/mL in the MK-677 group and from 236 +/- 19 to 174 +/- 23 ng/mL in the placebo group. Mean IGF-I concentration increased significantly during MK-677 to 264 +/- 31 ng/mL (mean for the last 5 days of treatment) compared with 188 +/- 19 ng/mL with placebo (P < 0.01). No significant difference in IGF binding protein-2 was found between the MK-677 and placebo treatments. However, the mean in IGF binding protein-3 for the last 5 days of MK-677 treatment was also significantly increased to 3273 +/- 330 ng/mL (mean +/- SE) compared with placebo 2604 +/- 253 ng/mL (P < 0.01). Neither the serum cortisol nor the PRL response was significantly greater after 7 days of MK-677 dosing compared with 7 days of placebo. MK-677 (25 mg) was generally well tolerated and without clinically significant adverse experiences. In conclusion, MK-677 reverses diet-induced nitrogen wasting, suggesting that if these short-term anabolic effects are maintained in patients who are catabolic because of certain acute or chronic disease states, it may be useful in treating catabolic conditions.

 

[John Juan]

The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.

Authors
Basaria S1, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, Ulloor J, Zhang A, Eder R, Zientek H, Gordon G, Kazmi S, Sheffield-Moore M, Bhasin S.
Author information
Journal
J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):87-95. doi: 10.1093/gerona/gls078. Epub 2012 Mar 28.

Affiliation
Abstract
BACKGROUND: Concerns about potential adverse effects of testosterone on prostate have motivated the development of selective androgen receptor modulators that display tissue-selective activation of androgenic signaling. LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity. Objectives. To evaluate the safety, tolerability, pharmacokinetics, and effects of ascending doses of LGD-4033 administered daily for 21 days on lean body mass, muscle strength, stair-climbing power, and sex hormones.

METHODS: In this placebo-controlled study, 76 healthy men (21-50 years) were randomized to placebo or 0.1, 0.3, or 1.0 mg LGD-4033 daily for 21 days. Blood counts, chemistries, lipids, prostate-specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength were measured during and for 5 weeks after intervention.

RESULTS: LGD-4033 was well tolerated. There were no drug-related serious adverse events. Frequency of adverse events was similar between active and placebo groups. Hemoglobin, prostate-specific antigen, aspartate aminotransferase, alanine aminotransferase, or QT intervals did not change significantly at any dose. LGD-4033 had a long elimination half-life and dose-proportional accumulation upon multiple dosing. LGD-4033 administration was associated with dose-dependent suppression of total testosterone, sex hormone-binding globulin, high density lipoprotein cholesterol, and triglyceride levels. follicle-stimulating hormone and free testosterone showed significant suppression at 1.0-mg dose only. Lean body mass increased dose dependently, but fat mass did not change significantly. Hormone levels and lipids returned to baseline after treatment discontinuation.

CONCLUSIONS: LGD-4033 was safe, had favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.

 

[minion1000]

What do you think? Would it be beneficial to use MK-677 along with liguid Tamox at the end of a 12 week cycle of test- enanthate( 500mg- weekly) to help restore proper body functions?? And if so what would a proper doesing schedule be in your opinion??. Im 215lbs ,6'1.